Review
doi: 10.2174/138920101506140910145940.
Biologics in polymyositis and dermatomyositis-associated interstitial lung disease
Affiliations
- PMID: 25213360
- DOI: 10.2174/138920101506140910145940
Item in Clipboard
Review
Biologics in polymyositis and dermatomyositis-associated interstitial lung disease
Curr Pharm Biotechnol.
2014.
Abstract
Interstitial lung disease (ILD) is one of the most common complications of polymyositis (PM) and dermatomyositis (DM). It is always progressive and does not respond to conventional immunosuppressive agent treatment. Biologics are commonly used in treatment of rheumatic diseases. They are also used in polymyositis and dermatomyositis associated interstitial lung disease. This review will focus on the updated use of biologics in PM/DM-ILD.
Similar articles
-
Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis.J Rheumatol. 2005 Jan;32(1):58-64. J Rheumatol. 2005. PMID: 15630726
-
Cyclosporine treatment for polymyositis/dermatomyositis: is it possible to rescue the deteriorating cases with interstitial pneumonitis?Scand J Rheumatol. 1997;26(1):24-9. doi: 10.3109/03009749709065660. Scand J Rheumatol. 1997. PMID: 9057798
-
Interleukin-18 is a key mediator in dermatomyositis: potential contribution to development of interstitial lung disease.Rheumatology (Oxford). 2010 Oct;49(10):1878-81. doi: 10.1093/rheumatology/keq196. Epub 2010 Jul 3. Rheumatology (Oxford). 2010. PMID: 20601655
-
Interstitial lung disease in polymyositis and dermatomyositis.Curr Opin Rheumatol. 2000 Nov;12(6):501-8. doi: 10.1097/00002281-200011000-00005. Curr Opin Rheumatol. 2000. PMID: 11092199 Review.
-
Interstitial lung disease in polymyositis and dermatomyositis.Curr Rheumatol Rep. 2005 Apr;7(2):99-105. doi: 10.1007/s11926-005-0061-4. Curr Rheumatol Rep. 2005. PMID: 15760588 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
